Evidence map›Paper›PMID 23262201›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2013

Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.

Rui Zhang, Kui Luo, Jiyuan Yang, Monika Sima, Yongen Sun, Margit M Janát-Amsbury, Jindřich Kopeček

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Thermoresponsive polymeric dexamethasone prodrug for arthritis pain.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  10. Article
  11. Review
  12. Polymer nanomedicines.Advanced drug delivery reviews · 2020
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Design of smart HPMA copolymer-based nanomedicines.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  19. Article
  20. Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rui ZhangDepartment of Pharmaceutics and Pharmaceutical Chemistry/CCCD, University of Utah, Salt Lake City, UT 84112, USA.
Kui Luo
Jiyuan Yang
Monika Sima
Yongen Sun
Margit M Janát-Amsbury
Jindřich Kopeček

Funding

Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian CancerR42CA156933 · NCI · THERATARGET · PI KOPECEK, JINDRICH H. · 2014 to 2015
$995k
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian CancerR41CA156933 · NCI · THERATARGET · PI CHENEY, DARWIN LEROY, KOPECEK, JINDRICH H. · 2011 to 2011
$148k
NCI NIH HHS CA156933NCI NIH HHS R41 CA156933NCI NIH HHS R42 CA156933
6 · The paper itself

Abstract

The performance and safety of current antineoplastic agents, particularly water-insoluble drugs, are still far from satisfactory. For example, the currently widely used Cremophor EL®-based paclitaxel (PTX) formulation exhibits pharmacokinetic concerns and severe side effects. Thus, the concept of a biodegradable polymeric drug-delivery system, which can significantly improve therapeutic efficacy and reduce side effects is advocated. The present work aims to develop a new-generation of long-circulating, biodegradable carriers for effective delivery of PTX. First, a multiblock backbone biodegradable N-(2-hydroxypropyl)methacrylamide(HPMA) copolymer-PTX conjugate (mP-PTX) with molecular weight (Mw) of 335 kDa was synthesized by RAFT (reversible addition-fragmentation chain transfer) copolymerization, followed by chain extension. In vitro studies on human ovarian carcinoma A2780 cells were carried out to investigate the cytotoxicity of free PTX, HPMA copolymer-PTX conjugate with Mw of 48 kDa (P-PTX), and mP-PTX. The experiments demonstrated that mP-PTX has a similar cytotoxic effect against A2780 cells as free PTX and P-PTX. To further compare the behavior of this new biodegradable conjugate (mP-PTX) with free PTX and P-PTX in vivo evaluation was performed using female nu/nu mice bearing orthotopic A2780 ovarian tumors. Pharmacokinetics study showed that high Mw mP-PTX was cleared more slowly from the blood than commercial PTX formulation and low Mw P-PTX. SPECT/CT imaging and biodistribution studies demonstrated biodegradability as well as elimination of mP-PTX from the body. The tumors in the mP-PTX treated group grew more slowly than those treated with saline, free PTX, and P-PTX (single dose at 20 mg PTX/kg equivalent). Moreover, mice treated with mP-PTX had no obvious ascites and body-weight loss. Histological analysis indicated that mP-PTX had no toxicity in liver and spleen, but induced massive cell death in the tumor. In summary, this biodegradable drug delivery system has a great potential to improve performance and safety of current antineoplastic agents.

Indexed as

AcrylamidesAcrylic ResinsAnimalsAntineoplastic Agents, PhytogenicBiocompatible MaterialsCell Line, TumorCell SurvivalDrug CarriersFemaleHumansMiceMice, NudeMolecular WeightNanoparticlesOvarian NeoplasmsPaclitaxelAcrylamidesAcrylic ResinsAntineoplastic Agents, PhytogenicBiocompatible MaterialsDrug CarriersN-(2-hydroxypropyl)methacrylamideN-(2-hydroxypropyl)methacrylamide copolymer-paclitaxel conjugatePaclitaxel

Identifiers

PMID23262201
PMCPMC3565036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.